Evoke Pharma (EVOK) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
March 7, 2018 4:05 PM ESTSuccessfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti doseAnnounced discovery of sex-based pharmacokinetic differences for GimotiMet with FDA regarding NDA women-only filing strategy and post-marketing plans505(b)(2) NDA submission planned for second quarter of 2018Â Â Â Â Â Â Â
SOLANA BEACH, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and full year ended... More
